Imatinib-induced lichenoid eruption: A case report and a review of literature

Authors

  • Thiraphong Mekwilaiphan Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
  • Natta Rajatanavin Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Keywords:

lichenoid eruption, tyrosine kinase inhibitor, Imatinib

Abstract

Imatinib is the first generation tyrosine kinase inhibitor which consisted of bcr-abl, c-kit, and platelet-derived growth factor receptors (PDGFRs). Its tolerability in the treatment of malignancies is higher than the conventional chemotherapy. However, various adverse cutaneous reactions are the most common side effect of imatinib. Nevertheless, lichenoid eruption is an uncommon cutaneous reaction from imatinib. The clinical manifestation is violaceous, flat-topped papules or plaques involving mainly trunk and extremities. Oral and genital mucosal involvement is a distinctive feature. There were no specific histopathological findings, but usually not a typical characteristic of lichen planus. Due to high prevalence of cutaneous rash, the pathogenesis may be related to pharmacological effect than hypersensitivity reaction. Dosage decrement of imatinib is a choice of treatment, or switch to the second or third generation tyrosine kinase inhibitors. Acitretin was successfully used to treat imatinib-induced lichenoid eruption in our patient and enabling the continuation of the high imatinib dosage for her hematologic malignancy.

References

1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010.

2. Jabbour E, Kantarjian H, Cortes J. Use of secondand third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15:323-34.

3. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 2014;71:217.e1-11.

4. Tang N, Ratner D. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatol Surg 2016;42:S40-8.

5. Atalay F, Kızılkılıç E, Ada RS. Imatinib-induced psoriasis. Turk J Haematol 2013;30:216-8.

6. Pretel-Irazabal M, Tuneu-Valls A, OrmaecheaPérez N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. Actas Dermosifiliogr 2014;105:655-62.

7. Park SR, Ryu MH, Ryoo BY, et al. Severe ImatinibAssociated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Res Treat 2016;48:162-70.

8. Zhang JA, Yu JB, Li XH, Zhao L. Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a Chinese patient with chronic myeloid leukemia. Ann Dermatol 2015;27:228-9.

9. Penn EH, Chung HJ, Keller M. Imatinib mesylateinduced lichenoid drug eruption. Cutis 2017;99:189-92.

10. Lee WJ, Lee JH, Won CH, Chang SE, Choi JH, Moon KC et al. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib. Int J Dermatol 2016;55:e268-74.

11. Brazzelli V, Grasso V, Borroni G. Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. J Eur Acad Dermatol Venereol 2013;27:1471-80.

12. Cho AY, Kim DH, Im M, et al. Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™). Ann Dermatol 2011;23:S360-3.

13. Bhatia A, Kanish B, Chaudhary P. Lichenoid drug eruption due to imatinib mesylate. Int J Appl Basic Med Res 2015;5:68-9.

14. Ghosh SK. Generalized lichenoid drug eruption associated with imatinib mesylate therapy. Indian J Dermatol 2013;58:388-92.

15. Dalmau J, Peramiquel L, Puig L, et al. Imatinibassociated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006;154:1213-6.

16. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 2011;24:386-95.

Downloads

Published

2017-12-01

How to Cite

Mekwilaiphan, T., & Rajatanavin, N. (2017). Imatinib-induced lichenoid eruption: A case report and a review of literature. Thai Journal of Dermatology, 33(4), 329–335. Retrieved from https://he02.tci-thaijo.org/index.php/TJD/article/view/159127

Issue

Vol. 33 No. 4 (2017): October - December

Section

Case Report

License

เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ

บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น